Several immune-related toxic effects have been reported with ipilimumab therapy for cutaneous melanoma. We describe a novel reaction, to our knowledge, involving the choroidal vasculature and resulting in bilateral serous retinal detachments without overt inflammatory signs.
A woman in her early 70s with acral lentiginous melanoma on her heel was initially treated with wide excision and sentinel lymph node resection followed by ipilimumab (3 mg/kg) adjuvant therapy per protocol. Prior to cycle 4 of ipilimumab therapy, she was found to have nodal recurrence. She underwent resection and cycle 4 was held per protocol as she was recovering from surgery. She was deemed to have no evidence of disease and received her first maintenance dose of ipilimumab per protocol during week 24.
Mantopoulos D, Kendra KL, Letson AD, Cebulla CM. Bilateral Choroidopathy and Serous Retinal Detachments During Ipilimumab Treatment for Cutaneous Melanoma. JAMA Ophthalmol. 2015;133(8):965–967. doi:10.1001/jamaophthalmol.2015.1128
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: